

#2  
 551 U.S. PTO  
 09/24/30  
 02/03/99

<b>INFORMATION DISCLOSURE STATEMENT</b> (37 C.F.R. 1.56, 1.97, and 1.98)	ATTORNEY DOCKET  23164-1001D1	APPLICATION NO.  To Be Assigned
	APPLICANT(S)  Michael Gerard Tovey	
	FILING DATE  February 3, 1999	GROUP  To Be Assigned

SHEET 1 OF 3

**U.S. PATENT DOCUMENTS**


† EX'R INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)	NAME	U.S. CLASS/ SUBCLASS	FILING DATE (If appropriate)
8	*1	4,605,555	08/86	Sato et al	424/85	
8	*2	5,019,382	05/91	Cummins, Jr.	424/85.4	
8	*3	5,215,741	06/93	Young et al.	424/85.7	
8	*4	5,286,748	02/94	Eby, III	514/494	
8	*5	5,017,371	05/91	Cummins	424/85.6	
8	*6	4,820,514	04/89	Cummins	424/85.4	
8	*7	5,188,828	02/93	Goldberg et al.	424/85.2	
8	*8	5,449,515	09/95	Hamilton et al.	424/85.2	
8	*9	5,601,814	02/97	Barton et al.	424/85.2	

**FOREIGN PATENT DOCUMENTS**

† EX'R INITIAL	* REF. #				TRANSLATION (YES/NO)
8	*10	CA 1,320,905	08/93	CANADA	YES
	*11	WO 91/16917	11/91	PCT	NO
	*12	WO 92/11030	07/92	PCT	NO
	*13	94/1654	03/94	REPUBLIC OF SOUTH AFRICA	NO
	*14	WO 96/10395	04/96	PCT	NO
	*15	WO 96/25171	08/96	PCT	NO
	*16	WO 97/25862	07/97	PCT	NO



**OTHER DOCUMENTS**

† EX'R INITIAL	* REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)
8	*17	Boguniewicz et al., "The Effect of Nebulized Recombinant Interferon-γ in Asthmatic Airways", <i>J. Allergy Clin. Immunol.</i> 95:133-135 (1995).

EXAMINER'S SIGNATURE 	DATE CONSIDERED 3/75/2002
--	------------------------------


† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. Include copy of this form in next communication to applicant.

\* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).

<b>INFORMATION DISCLOSURE STATEMENT</b> (37 C.F.R. 1.56, 1.97, and 1.98)		ATTORNEY DOCKET	APPLICATION NO.	
		23164-1001D1		To Be Assigned
		APPLICANT(S)		Michael Gerard Tovey
		FILING DATE	GROUP	
SHEET 2 OF 3		February 3, 1999	To Be Assigned	
<b>OTHER DOCUMENTS</b>				
† EX'R INITIAL	* REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)		
J	*18	Boguniewicz et al., "The Effect of Nebulized Recombinant Interferon- $\gamma$ in Asthmatic Airways", <i>J. Allergy Clin. Immunol.</i> 95:133-135 (1995).		
J	*19	Brod et al., "Oral Administration of IFN- $\alpha$ is Superior to Subcutaneous Administration of IFN- $\alpha$ in the Suppression of Chronic...", <i>Journal of Autoimmunity</i> 9:11-20 (1996).		
J	*20	Douglas et al., "Prophylactic Efficacy of Intranasal Alpha <sub>2</sub> -Interferon Against Rhinovirus Infections in the Family Setting" 314: 65-70 (1986).		
J	*21	Hayden et al., "Intranasal Interferon $\alpha_2$ for Prevention of Rhinovirus Infection and Illness", <i>Journal of Infectious Diseases</i> 148:543-550 (1983).		
J	*22	Hayden et al., "Human Tolerance and Histopathologic Effects of Long Term Administration of Intranasal Interferon- $\alpha_2$ ", <i>Journal of Infectious Diseases</i> 148:914-921 (1983).		
J	*23	Hayden et al., "Prevention of Natural colds by Contact Prophylaxis with Intranasal Alpha <sub>2</sub> -Interferon", <i>New England Journal Of Medicine</i> 314:71-75 (1986).		
J	*24	Hayden et al., "Human Nasal Mucosal Responses to Topically Applied Recombinant Leukocyte A Interferon", <i>Journal of Infectious Diseases</i> 156:64-72 (1987).		
J	*25	Iida et al., "Protective Activity of Recombinant Cytokines Against Sendai Virus and Herpes Simplex Virus (HSV) infections in mice", <i>Vaccine</i> 7:229-233 (1989).		
J	*26	Machida et al., "Absorption of recombinant human granulocyte colony-stimulating factor (rhG-CSF) from rat nasal mucosa," <i>Pharmaceutical Research</i> , 10:1372-1377 (1993).		
J	*27	Matsuzawa et al., "Protective Effect of Mucosal Administration of Recombinant Human Macrophage Colony-Stimulating Factor...", <i>Vaccine</i> 15:85-89 (1997).		
J	*28	Moore et al., "Inflammatory Markers in Bronchoalveolar Lavage Fluid of Standardbred Racehorses with Inflammatory...", <i>Equine Veterinary Journal</i> 29:142-147 (1997).		
J	*29	Oehling et al., "Suppression of the Immune System by Oral Glucocorticoid Therapy in Bronchial Asthma", <i>Allergy</i> 52:144-154.		
EXAMINER'S SIGNATURE		DATE CONSIDERED		
				
† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. <i>Include copy of this form in next communication to applicant.</i>				
* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).				

<b>INFORMATION DISCLOSURE STATEMENT</b> (37 C.F.R. 1.56, 1.97, and 1.98)		ATTORNEY DOCKET	APPLICATION NO.
		23164-1001D1	To Be Assigned
		APPLICANT(S)	
		Michael Gerard Tovey	
SHEET 3 OF 3		FILING DATE	GROUP
		February 3, 1999	To Be Assigned


OTHER DOCUMENTS		
† EX'R INITIAL	* REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)
Q	*30	Samo et al., "Efficacy and Tolerance of Intranasally Applied Recombinant Leukocyte A Interferon in Normal Volunteers", <i>Journal of Infectious Diseases</i> 148:535-542 (1983).
Q	*31	Samo et al., "Intranasally Applied Recombinant Leukocyte A Interferon in Normal Volunteers. II.", <i>Journal of Infectious Diseases</i> 150:181-188 (1984).
Q	*32	Soos et al., Oral Feeding of Interferon $\tau$ Can Prevent the Acute and Chronic Relapsing Forms of Experimental Allergic Encephalomyelitis", <i>Journal of Neuroimmunology</i> 75:43-50 (1997).
Q	*33	Takada et al., "Pharmacological Activity of Tablets Containing Recombinant Human Granulocyte...", <i>International Journal of Pharmaceutics</i> 101:89-96 (1994).
Q	*34	Vriesendorp et al., "Oral Administration of Type I Interferon Modulates the Course of Experimental Allergic Neuritis", <i>Autoimmunity</i> 24:157-165 (1996).
Q	*35	Watanabe et al., "Absorption and Blood Leukocyte Dynamics of Recombinant Human Granulocyte Colony-Stimulating Factor...", <i>International Journal of Pharmaceutics</i> 110:93-97 (1994).
Q	*36	Zielinska et al., "Comparison of the Long-Term Effects of Treatment with Oral and Parenteral...", <i>Archivum Immunologiae et Therapiae Experimentalis</i> 44:359-366 (1996).
Q	*37	Ianaro, et al., "Expression of TGF- $\beta$ in attenuated <i>Salmonella typhimurium</i> : oral administration leads to the reduction of inflammation, IL-2 and IFN- $\gamma$ , but enhancement of IL-10, in carrageenin-induced oedema in mice," <i>Immunology</i> , 84:8-15 (1995).
Q	*38	Koren et al., "Modulation of peripheral leukocyte counts and bone marrow function in mice by oral administration of interleukin-2," <i>Journal of Interferon Research</i> , 14:343-347 (1994).
Q	*39	Marinero et al., "Interleukin-12 alters helper T-cell subsets and antibody profiles induced by the mucosal adjuvant cholera toxin," <i>Annals New York Academy of Sciences</i> , __:361-365 (__).
Q	*40	Marinero et al., "Oral but not parenteral interleukin (IL)-12 redirects T helper 2 (Th2)-type responses to an oral vaccine without latering mucosal IgA responses," <i>J. Exp. Med.</i> , 185:415-427 (1997).
Q	*41	Yamamoto et al., "TNF/LT- $\alpha$ double knockout mice have deficient Th2 type immunity but retain Th1 function," <i>J. Allergy Clin. Immunol.</i> , Abstract, 143 (1997).
EXAMINER'S SIGNATURE		DATE CONSIDERED
		3/15/2000
† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. Include copy of this form in next communication to applicant.		
* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).		



# INFORMATION DISCLOSURE STATEMENT

(37 C.F.R. 1.56, 1.97, and 1.98)

SHEET 1 OF 1



ATTORNEY DOCKET

23164-1001-D

APPLICATION NO.

09/243,030

APPLICANT(S)

Tovey, Michael G.

February 3, 1999

GROUP

1646

## U.S. PATENT DOCUMENTS

† EX'R INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)	NAME	U.S. CLASS/ SUBCLASS	FILING DATE (If appropriate)

## FOREIGN PATENT DOCUMENTS

† EX'R INITIAL	* REF. #				TRANSLATION (YES/NO)
	1	WO 82/00588	4/82	PCT	
	2	WO 92/10207	6/92	PCT	
	3	0 396 903	3/90	EPO	

## OTHER DOCUMENTS

† EX'R INITIAL	* REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)
	4	Hayden, Frederick G., "Intranasal Interferon $\alpha 2$ for Prevention of Rhinovirus Infection and Illness", The Journal of Infectious Diseases, Vol. 148, No. 3 September 1983. pp. 543-550.

EXAMINER'S SIGNATURE

DATE CONSIDERED

*[Handwritten Signature]*

3/15/2000

† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. Include copy of this form in next communication to applicant.